Invivyd Inc. Announces New Clinical Study to Evaluate Monoclonal Antibody Therapy for Long COVID at RECOVER-TLC Workshop
Invivyd, Inc. (Nasdaq: IVVD) has announced that the SPEAR Study Group has put forward a consensus recommendation for a clinical study design aimed at evaluating the effects of monoclonal antibody therapy on Long COVID. This proposed study, which centers on the use of anti-SARS-CoV-2 spike protein monoclonal antibodies, including Invivyd's VYD2311, will be presented at the Second Annual RECOVER-TLC Workshop, scheduled for September 9-10, 2025, in Bethesda, Maryland. The SPEAR Study Group's proposal reflects current evidence on the potential of monoclonal antibodies in treating Long COVID and identifies VYD2311 as a promising candidate. The study design is set to maintain high antiviral antibody titers over an extended period to suppress chronic infection potentially driving Long COVID. Drs. Amy Proal and David Putrino will present the study design for consideration by RECOVER-TLC, with Dr. Putrino scheduled to present the clinical study design on September 10, 2025, at 9:25 a.m. ET, followed by Dr. Proal's discussion on the antiviral landscape at 1:00 p.m. ET on the same day.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Invivyd Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9523078-en) on September 04, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.